Nektar Therapeutics Debt Securities, Available-for-sale, Current
Nektar Therapeutics (NKTR) had Debt Securities, Available-for-sale, Current of $645.07 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-08-14
- 2026-06-30: Debt Securities, Available-for-sale, Current $645.07M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $419.03M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $230.64M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $229.18M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $645.07M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $419.03M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $230.64M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $229.18M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $132.91M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $179.74M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $210.97M 10-K · filed 2026-03-13 |
| 2024-09-30 | $214.39M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $243.29M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $240.60M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $268.34M 10-K · filed 2025-03-14 |
| 2023-09-30 | $307.74M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $358.70M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $379.87M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $416.75M 10-K · filed 2024-03-05 |
| 2022-09-30 | $440.63M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $541.77M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $599.03M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $708.74M 10-K · filed 2023-02-28 |
| 2021-09-30 | $867.06M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $847.72M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $887.15M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $862.94M 10-K · filed 2022-03-01 |
| 2020-09-30 | $900.16M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $980.19M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $1.12B 10-Q · filed 2020-05-08 |
| 2019-12-31 | $1.23B 10-K · filed 2021-02-26 |
| 2019-09-30 | $1.41B 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.43B 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.28B 10-Q · filed 2019-05-09 |
| 2018-12-31 | $1.14B 10-K · filed 2020-02-28 |
| 2018-09-30 | $1.20B 10-Q · filed 2018-11-08 |
| 2017-12-31 | $291.37M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |